
Statins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
Description
Statins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
North America Dominates the Market, with the United States Leading in Statin Usage
• Rising Obesity and Cardiovascular Disease Cases Boost Demand for Statins Worldwide
The global statins market is on a steady growth trajectory and is expected to reach a valuation of US$ 21 billion by 2031. In 2024, the market was valued at US$ 15.4 billion.
Market Dynamics
The global demand for statins is being significantly influenced by the increasing incidence of high cholesterol and obesity cases worldwide. Lifestyle changes and sedentary habits have led to a rise in high cholesterol levels, making statins an essential solution for cholesterol management.
Statins play a crucial role in addressing high cholesterol levels that are difficult to control solely through lifestyle modifications. Additionally, awareness initiatives and advanced healthcare facilities are contributing to the growing demand for statins.
Moreover, the adoption of combination therapies that include statins alongside other cholesterol-lowering medications, such as ezetimibe, is expected to further drive the global market. Statin-ezetimibe combination therapy has shown promise in achieving near-normal lipid profiles, reducing the risk of cardiovascular diseases.
Challenges and Opportunities
While the statins market is poised for growth, challenges persist, primarily related to high manufacturing costs and the complexity of the production process. Additionally, establishing biosimilarity through rigorous analytical characterization and regulatory approval procedures remains a time-consuming and costly process.
However, increasing investments in research and development, a strong focus on improving healthcare facilities, and strategic collaborations between public and private entities are expected to provide growth opportunities for statin manufacturers.
Regional Analysis
North America is at the forefront of the global statins market and is poised to maintain its dominance throughout the forecast period. The region has a significant population suffering from cardiovascular diseases, diabetes, and obesity, driving the demand for effective cholesterol management solutions.
The United States is expected to lead the statins market in North America, with organizations like the American Heart Association and the American College of Cardiology issuing guidelines that recommend statin usage for individuals at risk of heart attacks.
Product Analysis
Statins are a class of drugs used to lower blood cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol. The market for statins has witnessed steady growth, driven by increased healthcare awareness and the rising prevalence of cholesterol-related conditions.
While maintaining a healthy lifestyle can help manage cholesterol, sedentary habits have contributed to a growing need for statin therapy, particularly among the elderly population.
Key Players
Prominent players in the global statins market include Pfizer Inc., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Merck & Co., Inc., Biocon, Aurobindo Pharma Ltd, and Concord Biotech.
Statins Industry Research Segmentation
By Drug Class:
• Astrovastatins
• Fluvastatins
• Lovastatins
• Pravastatins
• Simvastatins
• Others
By Therapeutic Treatment:
• Cardiovascular Disorders
• Obesity
• Inflammatory Disorders
• Others
By End User:
• Hospitals
• Clinics
By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.
Table of Contents
250 Pages
- 1. Executive Summary
- 1.1. Global Biosimilars Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value and Volume, 2023
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. Production Output and Trade Statistics, 2018 – 2023
- 3.1. Global Biosimilars Production Output, by Region, Value (US$ Bn) and Volume (Units), 2018 – 2023
- 3.1.1. North America
- 3.1.2. Europe
- 3.1.3. Asia Pacific
- 3.1.4. Latin America
- 3.1.5. Middle East and Africa
- 4. Price Analysis, 2018 – 2023
- 4.1. Global Average Price Analysis by Product Type, 2018 – 2023
- 4.2. Prominent Factor Affecting Biosimilars Prices
- 4.3. Global Average Price Analysis by Region
- 5. Global Biosimilars Market Outlook, 2018 – 2031
- 5.1. Global Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 5.1.1. Key Highlights
- 5.1.1.1. Recombinant Glycosylated Proteins
- 5.1.1.2. Recombinant Non-Glycosylated Proteins
- 5.2. Global Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 5.2.1. Key Highlights
- 5.2.1.1. Hematology
- 5.2.1.2. Growth Hormone Deficiency
- 5.2.1.3. Oncology
- 5.2.1.4. Diabetes Autoimmune
- 5.2.1.5. Disease
- 5.2.1.6. Others
- 5.3. Global Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 5.3.1. Key Highlights
- 5.3.1.1. Hospital Pharmacies
- 5.3.1.2. Online Pharmacies
- 5.3.1.3. Retail Pharmacies
- 5.4. Global Biosimilars Market Outlook, by Region, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 5.4.1. Key Highlights
- 5.4.1.1. North America
- 5.4.1.2. Europe
- 5.4.1.3. Asia Pacific
- 5.4.1.4. Latin America
- 5.4.1.5. Middle East & Africa
- 6. North America Biosimilars Market Outlook, 2018 – 2031
- 6.1. North America Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 6.1.1. Key Highlights
- 6.1.1.1. Recombinant Glycosylated Proteins
- 6.1.1.2. Recombinant Non-Glycosylated Proteins
- 6.2. North America Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 6.2.1. Key Highlights
- 6.2.1.1. Hematology
- 6.2.1.2. Growth Hormone Deficiency
- 6.2.1.3. Oncology
- 6.2.1.4. Diabetes Autoimmune
- 6.2.1.5. Disease
- 6.2.1.6. Others
- 6.3. North America Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 6.3.1. Key Highlights
- 6.3.1.1. Hospital Pharmacies
- 6.3.1.2. Online Pharmacies
- 6.3.1.3. Retail Pharmacies
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
- 6.4. North America Biosimilars Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 6.4.1. Key Highlights
- 6.4.1.1. U.S. Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 6.4.1.2. U.S. Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 6.4.1.3. U.S. Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 6.4.1.4. Canada Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 6.4.1.5. Canada Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 6.4.1.6. Canada Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
- 7. Europe Biosimilars Market Outlook, 2018 – 2031
- 7.1. Europe Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.1.1. Key Highlights
- 7.1.1.1. Recombinant Glycosylated Proteins
- 7.1.1.2. Recombinant Non-Glycosylated Proteins
- 7.2. Europe Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.2.1. Key Highlights
- 7.2.1.1. Hematology
- 7.2.1.2. Growth Hormone Deficiency
- 7.2.1.3. Oncology
- 7.2.1.4. Diabetes Autoimmune
- 7.2.1.5. Disease
- 7.2.1.6. Others
- 7.3. Europe Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.3.1. Key Highlights
- 7.3.1.1. Hospital Pharmacies
- 7.3.1.2. Online Pharmacies
- 7.3.1.3. Retail Pharmacies
- 7.3.2. Attractiveness Analysis
- 7.4. Europe Biosimilars Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1. Key Highlights
- 7.4.1.1. Germany Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.2. Germany Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.3. Germany Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.4. U.K. Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.5. U.K. Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.6. U.K. Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.7. France Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.8. France Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.9. France Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.10. Italy Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.11. Italy Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.12. Italy Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.13. Turkey Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.14. Turkey Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.15. Turkey Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.16. Russia Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.17. Russia Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.18. Russia Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.19. Rest of Europe Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.20. Rest of Europe Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.1.21. Rest of Europe Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
- 8. Asia Pacific Biosimilars Market Outlook, 2018 – 2031
- 8.1. Asia Pacific Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.1.1. Key Highlights
- 8.1.1.1. Recombinant Glycosylated Proteins
- 8.1.1.2. Recombinant Non-Glycosylated Proteins
- 8.2. Asia Pacific Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.2.1. Key Highlights
- 8.2.1.1. Hematology
- 8.2.1.2. Growth Hormone Deficiency
- 8.2.1.3. Oncology
- 8.2.1.4. Diabetes Autoimmune
- 8.2.1.5. Disease
- 8.2.1.6. Others
- 8.3. Asia Pacific Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.3.1. Key Highlights
- 8.3.1.1. Hospital Pharmacies
- 8.3.1.2. Online Pharmacies
- 8.3.1.3. Retail Pharmacies
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
- 8.4. Asia Pacific Biosimilars Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1. Key Highlights
- 8.4.1.1. China Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.2. China Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.3. China Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.4. Japan Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.5. Japan Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.6. Japan Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.7. South Korea Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.8. South Korea Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.9. South Korea Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.10. India Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.11. India Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.12. India Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.13. Southeast Asia Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.14. Southeast Asia Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.15. Southeast Asia Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.16. Rest of Asia Pacific Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.17. Rest of Asia Pacific Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.1.18. Rest of Asia Pacific Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
- 9. Latin America Biosimilars Market Outlook, 2018 – 2031
- 9.1. Latin America Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.1.1. Key Highlights
- 9.1.1.1. Recombinant Glycosylated Proteins
- 9.1.1.2. Recombinant Non-Glycosylated Proteins
- 9.2. Latin America Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.2.1. Key Highlights
- 9.2.1.1. Hematology
- 9.2.1.2. Growth Hormone Deficiency
- 9.2.1.3. Oncology
- 9.2.1.4. Diabetes Autoimmune
- 9.2.1.5. Disease
- 9.2.1.6. Others
- 9.3. Latin America Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.3.1. Key Highlights
- 9.3.1.1. Hospital Pharmacies
- 9.3.1.2. Online Pharmacies
- 9.3.1.3. Retail Pharmacies
- 9.3.2. BPS Analysis/Market Attractiveness Analysis
- 9.4. Latin America Biosimilars Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1. Key Highlights
- 9.4.1.1. Brazil Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1.2. Brazil Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1.3. Brazil Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1.4. Mexico Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1.5. Mexico Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1.6. Mexico Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1.7. Argentina Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1.8. Argentina Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1.9. Argentina Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1.10. Rest of Latin America Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1.11. Rest of Latin America Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.1.12. Rest of Latin America Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 9.4.2. BPS Analysis/Market Attractiveness Analysis
- 10. Middle East & Africa Biosimilars Market Outlook, 2018 – 2031
- 10.1. Middle East & Africa Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.1.1. Key Highlights
- 10.1.1.1. Recombinant Glycosylated Proteins
- 10.1.1.2. Recombinant Non-Glycosylated Proteins
- 10.2. Middle East & Africa Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.2.1. Key Highlights
- 10.2.1.1. Hematology
- 10.2.1.2. Growth Hormone Deficiency
- 10.2.1.3. Oncology
- 10.2.1.4. Diabetes Autoimmune
- 10.2.1.5. Disease
- 10.2.1.6. Others
- 10.3. Middle East & Africa Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.3.1. Key Highlights
- 10.3.1.1. Hospital Pharmacies
- 10.3.1.2. Online Pharmacies
- 10.3.1.3. Retail Pharmacies
- 10.3.2. BPS Analysis/Market Attractiveness Analysis
- 10.4. Middle East & Africa Biosimilars Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1. Key Highlights
- 10.4.1.1. GCC Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.2. GCC Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.3. GCC Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.4. South Africa Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.5. South Africa Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.6. South Africa Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.7. Egypt Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.8. Egypt Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.9. Egypt Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.10. Nigeria Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.11. Nigeria Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.12. Nigeria Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.13. Rest of Middle East & Africa Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.14. Rest of Middle East & Africa Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.1.15. Rest of Middle East & Africa Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 – 2031
- 10.4.2. BPS Analysis/Market Attractiveness Analysis
- 11. Competitive Landscape
- 11.1. By End User vs by Application Heatmap
- 11.2. Company Market Share Analysis, 2023
- 11.3. Competitive Dashboard
- 11.4. Company Profiles
- 11.4.1. Pfizer Inc.
- 11.4.1.1. Company Overview
- 11.4.1.2. Product Portfolio
- 11.4.1.3. Financial Overview
- 11.4.1.4. Business Strategies and Development
- 11.4.2. Sandoz International GMBH
- 11.4.2.1. Company Overview
- 11.4.2.2. Product Portfolio
- 11.4.2.3. Financial Overview
- 11.4.2.4. Business Strategies and Development
- 11.4.3. Eli Lily & Company
- 11.4.3.1. Company Overview
- 11.4.3.2. Product Portfolio
- 11.4.3.3. Financial Overview
- 11.4.3.4. Business Strategies and Development
- 11.4.4. Hospira Inc.
- 11.4.4.1. Company Overview
- 11.4.4.2. Product Portfolio
- 11.4.4.3. Financial Overview
- 11.4.4.4. Business Strategies and Development
- 11.4.5. Biocon Ltd.
- 11.4.5.1. Company Overview
- 11.4.5.2. Product Portfolio
- 11.4.5.3. Financial Overview
- 11.4.5.4. Business Strategies and Development
- 11.4.6. Actavis, Inc.
- 11.4.6.1. Company Overview
- 11.4.6.2. Product Portfolio
- 11.4.6.3. Financial Overview
- 11.4.6.4. Business Strategies and Development
- 11.4.7. Cipla Ltd
- 11.4.7.1. Company Overview
- 11.4.7.2. Product Portfolio
- 11.4.7.3. Financial Overview
- 11.4.7.4. Business Strategies and Development
- 11.4.8. Teva Pharmaceutical Industries, Ltd.
- 11.4.8.1. Company Overview
- 11.4.8.2. Product Portfolio
- 11.4.8.3. Financial Overview
- 11.4.8.4. Business Strategies and Development
- 11.4.9. Dr. Reddy’s Laboratories Ltd
- 11.4.9.1. Company Overview
- 11.4.9.2. Product Portfolio
- 11.4.9.3. Financial Overview
- 11.4.9.4. Business Strategies and Development
- 11.4.10. Celltrion, Inc.
- 11.4.10.1. Company Overview
- 11.4.10.2. Product Portfolio
- 11.4.10.3. Financial Overview
- 11.4.10.4. Business Strategies and Development
- 11.4.11. Stada Arzeimittel Ag
- 11.4.11.1. Company Overview
- 11.4.11.2. Product Portfolio
- 11.4.11.3. Financial Overview
- 11.4.11.4. Business Strategies and Development
- 11.4.12. Mylan, Inc.
- 11.4.12.1. Company Overview
- 11.4.12.2. Product Portfolio
- 11.4.12.3. Financial Overview
- 11.4.12.4. Business Strategies and Development
- 11.4.13. Wockhardt Ltd.
- 11.4.13.1. Company Overview
- 11.4.13.2. Product Portfolio
- 11.4.13.3. Financial Overview
- 11.4.13.4. Business Strategies and Development
- 12. Appendix
- 12.1. Research Methodology
- 12.2. Report Assumptions
- 12.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.